China-based WuXi Biologics (HKG: 2269) has announced a strategic partnership with Sweden-headquartered Pharmadule Morimatsu AB (HKG: 2155), focusing on the expansion of its Contract Research, Development, and Manufacturing Organization (CRDMO) service center in Singapore. The collaboration encompasses key project lifecycle processes, including design, manufacturing, FAT (Factory Acceptance Test), installation, debugging, and validation. Financial details of the partnership have not been disclosed.
WuXi Biologics’ Singapore Expansion and Job Creation
WuXi Biologics established its presence in Singapore with a RMB380 million facility in May 2018, following its initial overseas expansion in Ireland. The company’s USD1.4 billion CRDMO service center in Singapore is projected to be completed within a decade and is expected to create approximately 1500 jobs. By 2026, the center aims to add 120,000 liters of biopharmaceutical production capacity, significantly boosting the region’s biopharmaceutical industry.
Pharmadule Morimatsu AB’s Expertise in Digital Intelligent Chemical Plants
Morimatsu is a diversified multinational company with a strong foundation in core technologies and extensive project experience in the realms of core equipment, process systems, and solutions for digital intelligent chemical plants. Pharmadule Morimatsu, a specialized unit within the Morimatsu group, is renowned for providing modular and integrated solutions tailored for digital intelligent chemical plants. This expertise positions Pharmadule Morimatsu AB as a valuable partner in WuXi Biologics’ ambitious CRDMO service center project in Singapore.-Fineline Info & Tech
